Adaptive Biotechnologies (NASDAQ: ADPT) reported Q3 EPS of ($0.32), $0.06 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $47.8 million versus the consensus estimate of $49.05 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2022 revenue of $185-190 million, versus the consensus of $187.5 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.